Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05493280 · ClinicalTrials.gov registry record · NA

Fractionated 1927nm Laser for Hyperpigmentation in Fitzpatrick Skin Phototypes V and VI

A NA study of Hyperpigmentation, sponsored by University of Texas Southwestern Medical Center.

Completed
Registry status
NA
Development phase
15
Enrollment target
1
Study location

NCT05493280 is a NA study of Hyperpigmentation that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 15 participants, below the 33-participant average among 5 other Hyperpigmentation trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05493280, a NA study of Hyperpigmentation, has completed, sponsored by University of Texas Southwestern Medical Center.

COMPLETED
Registry status
NA
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

The primary objective of this study is to assess the efficacy of 1927nm non-ablative fractionated laser therapy to treat hyperpigmentation in patients ages 18-75 with Fitzpatrick Skin Phototypes V and VI and explore an effective, adjunctive pre- and post-procedural regimen to prevent iatrogenic dyspigmentation or scarring in this population.

Conditions Studied

Interventions

  • DEVICE MOXI

Study Locations (1)

Texas

  • UT Southwestern Medical Center- Dept of Plastic Surgery - Dallas

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2022-11-14
Est. Completion 2024-12-31
Phase NA

What the Registry Record Tells You About NCT05493280

The ClinicalTrials.gov registry entry for NCT05493280 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 33-participant average among 5 other Hyperpigmentation trials with a reported enrollment target (55% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hyperpigmentation appearing as the primary indexed condition, and to 1 intervention - of which MOXI is the first listed.

NCT05493280 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT05493280 about?

NCT05493280 is a clinical study titled "Fractionated 1927nm Laser for Hyperpigmentation in Fitzpatrick Skin Phototypes V and VI". The primary objective of this study is to assess the efficacy of 1927nm non-ablative fractionated laser therapy to treat hyperpigmentation in patients ages 18-75 with Fitzpatrick Skin Phototypes V and VI and explore an effective, adjunctive pre- and post-procedural regimen to prevent iatrogenic dysp...

What is the current status of trial NCT05493280?

This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2022-11-14. Estimated completion is 2024-12-31.

What conditions does trial NCT05493280 study?

This clinical trial studies the following conditions: Hyperpigmentation.

What interventions are being tested in trial NCT05493280?

The interventions under investigation include: MOXI (DEVICE).

Who is sponsoring clinical trial NCT05493280?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05493280 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hyperpigmentation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.